Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
about
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyGenetically modified T cells for the treatment of malignant diseaseCancer vaccines and T cell therapyAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookEngineered T cells for cancer treatmentFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceStrategies to genetically engineer T cells for cancer immunotherapy.The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins.Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.Improving the safety of cell therapy with the TK-suicide geneAffinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Mesothelin-targeted agents in clinical trials and in preclinical development.Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.Transgelin-2 in B-Cells Controls T-Cell Activation by Stabilizing T Cell - B Cell Conjugates.Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.Cancer immunotherapy: Progress and challenges in the clinical setting.Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.Chimeric Antigen Receptor T Cell Therapy in Hematology.Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.CAR T cells for acute myeloid leukemia: the LeY of the land.Design and development of therapies using chimeric antigen receptor-expressing T cellsRetargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.Chimeric antigen receptors (CARs) from bench-to-bedside.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.Challenges in T cell receptor gene therapy.The sweet side of tumor immunotherapy.Adoptive immunotherapy of advanced melanoma.Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.CAR T-cell therapy: toxicity and the relevance of preclinical models.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsChimeric Antigen Receptors for Cancer Immunotherapy.Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.mRNA Cancer Vaccines.Engineering CAR-T cells.MYCN: from oncoprotein to tumor-associated antigenHuman CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.ImmTACs: Novel bi-specific agents for targeted cancer therapy.
P2860
Q26823515-97E5354F-A40B-438D-A344-426E8E0E25DEQ26860657-05B09E82-A10D-4927-A909-CE80FC43A8C8Q26995638-A5380FBE-3558-4F06-B128-06131E376177Q27004178-D456183B-07B5-4BD1-927E-69F002965F28Q33578792-2349F698-A423-4428-9CF8-63390025DE36Q33607015-DC0B6F1B-C21E-4A2A-AD71-54336FA53FA7Q33655849-26559F59-625A-43D7-94D6-54D8BB489668Q34146327-4102BB0A-CC63-430D-ADC1-BC17CB5334E4Q34171679-5C4F29B9-FE03-4526-A3AF-2C44C3C0D955Q34235597-6A8F54F0-7DDD-487B-9338-D0D874E26FA2Q34477411-91457324-B686-4C88-B7B2-40EFAE837453Q35634680-97719F19-B620-4ACD-A134-E72B77E4CD71Q35815380-27F7EBBD-1C4F-49F6-B4CF-58CFFF556060Q35917978-4232EE43-9FEC-4B51-8A19-77D040103BDBQ36032528-1867173D-2E87-440F-920F-6C0EE0973DA9Q36067524-A4E26193-0267-4D8A-AF69-72C70C9F261DQ36184314-FCA6DA06-EEF4-4999-9D80-BC8E04FDE8C9Q36618810-B05394B0-E97E-43A9-9D9D-F290CD81C316Q36722700-39079486-73FB-4404-9B15-44DC265C6E33Q36882726-736EF262-75AD-4EE7-8CE9-A39D7AC8CCE8Q37042225-D0840FCF-F456-4C66-9A36-AE0B09E6C3F5Q37316892-744F86B7-DF75-472E-ACBB-692F0DA52A06Q37418289-44E84A5B-651F-407D-9990-86978F31868BQ37434670-EBF7663B-57C2-4F66-BEA6-78EB6B1091B9Q37587780-827CBFF8-CD96-41C7-8D9C-826B94336BA0Q37937083-8FC149F1-B82A-465D-BDA1-B9268681FD9CQ38011650-5D44CDB4-2B57-4F61-A1C6-0A8D3674FF5EQ38031282-E53CF386-A749-477C-BFC5-2431FB4D09EFQ38032141-410AC82F-9C57-4020-AC0B-B0309B302572Q38035043-8037B95F-F63A-4563-9DDC-8A3627E155AEQ38221692-0D8BF026-C99D-46F8-8D32-73C7EAC40DFCQ38525018-6D9337E2-C579-47D5-8F17-3CB850DD4A14Q38766349-F03DA09B-0224-4FFB-8D03-E67F0A3BC739Q38795058-1090AED9-CF6D-4B73-B698-0B655CADEAEBQ38873430-619E7A1C-05D6-4B77-A654-19B42325E6D2Q39013357-619D535B-ECFF-4240-B9FC-DDC9293BD1D9Q39399864-F0AC83E3-14C3-4AF3-B15A-A8794DF441DAQ41111508-58225FDF-2ED6-41C7-8664-F984EF1913EDQ41660817-5976D102-EE5A-4DEB-8874-4791B8B906AEQ43225889-B555F097-363A-4892-85E7-6979A805B869
P2860
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
@en
Chimeric antigen receptor
@nl
type
label
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
@en
Chimeric antigen receptor
@nl
prefLabel
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
@en
Chimeric antigen receptor
@nl
P2860
P1476
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
@en
P2093
Gianpietro Dotti
P2860
P304
P356
10.1517/14712598.2011.573476
P407
P577
2011-04-04T00:00:00Z